{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:50:25Z","timestamp":1785387025464,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173898"],"award-info":[{"award-number":["No. 82173898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]},{"name":"Institutional foundation of the first affiliated hospital of Xi'an Jiaotong University","award":["No. 2019ZYTS-01"],"award-info":[{"award-number":["No. 2019ZYTS-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00228-024-03698-2","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T09:02:33Z","timestamp":1715158953000},"page":"1241-1251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Estimation of linezolid exposure in patients with hepatic impairment using machine learning based on a population pharmacokinetic model"],"prefix":"10.1007","volume":"80","author":[{"given":"Ru","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"Suppl 2","key":"3698_CR1","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/jac\/dkg249","volume":"51","author":"DM Livermore","year":"2003","unstructured":"Livermore DM (2003) Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 51(Suppl 2):ii9-16. https:\/\/doi.org\/10.1093\/jac\/dkg249","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3698_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","volume":"59","author":"D Clemett","year":"2000","unstructured":"Clemett D, Markham A (2000) Linezolid. Drugs 59(4):815\u2013827; discussion 828. https:\/\/doi.org\/10.2165\/00003495-200059040-00007","journal-title":"Drugs"},{"issue":"2","key":"3698_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","volume":"138","author":"RC Moellering","year":"2003","unstructured":"Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138(2):135\u2013142. https:\/\/doi.org\/10.7326\/0003-4819-138-2-200301210-00015","journal-title":"Ann Intern Med"},{"issue":"2","key":"3698_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0038-1657751","volume":"38","author":"L Yang","year":"2018","unstructured":"Yang L, Wu T, Li J, Li J (2018) Bacterial infections in acute-on-chronic liver failure. Semin Liver Dis 38(2):121\u2013133. https:\/\/doi.org\/10.1055\/s-0038-1657751","journal-title":"Semin Liver Dis"},{"issue":"9","key":"3698_CR5","first-page":"1014","volume":"28","author":"MA Wynalda","year":"2000","unstructured":"Wynalda MA, Hauer MJ, Wienkers LC (2000) Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 28(9):1014\u20131017","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"3698_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/ftd.0000000000000665","volume":"41","author":"S Luque","year":"2019","unstructured":"Luque S, Mu\u00f1oz-Bermudez R, Echeverr\u00eda-Esnal D, Sorli L, Campillo N, Mart\u00ednez-Casanova J, Gonz\u00e1lez-Colominas E, \u00c1lvarez-Lerma F, Horcajada JP, Grau S, Roberts JA (2019) Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity. Ther Drug Monit 41(6):732\u2013739. https:\/\/doi.org\/10.1097\/ftd.0000000000000665","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3698_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00228-022-03427-7","volume":"79","author":"R Liao","year":"2023","unstructured":"Liao R, Dong Y, Chen L, Wang T, Li H, Dong H (2023) A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure. Eur J Clin Pharmacol 79(1):149\u2013157. https:\/\/doi.org\/10.1007\/s00228-022-03427-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3698_CR8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/aac.01185-10","volume":"55","author":"T Sasaki","year":"2011","unstructured":"Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I (2011) Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia. Japanese patients Antimicrob Agents Chemother 55(5):1867\u20131873. https:\/\/doi.org\/10.1128\/aac.01185-10","journal-title":"Japanese patients Antimicrob Agents Chemother"},{"issue":"15","key":"3698_CR9","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","volume":"42","author":"CR Rayner","year":"2003","unstructured":"Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42(15):1411\u20131423. https:\/\/doi.org\/10.2165\/00003088-200342150-00007","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3698_CR10","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/aac.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54(11):4605\u20134610. https:\/\/doi.org\/10.1128\/aac.00177-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3698_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/ftd.0000000000000324","volume":"38","author":"C T\u00f6pper","year":"2016","unstructured":"T\u00f6pper C, Steinbach CL, Dorn C, Kratzer A, Wicha SG, Schleibinger M, Liebchen U, Kees F, Salzberger B, Kees MG (2016) Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions. Ther Drug Monit 38(5):573\u2013578. https:\/\/doi.org\/10.1097\/ftd.0000000000000324","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3698_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","volume":"37","author":"M Peck-Radosavljevic","year":"2017","unstructured":"Peck-Radosavljevic M (2017) Thrombocytopenia in chronic liver disease. Liver Int 37(6):778\u2013793. https:\/\/doi.org\/10.1111\/liv.13317","journal-title":"Liver Int"},{"issue":"7","key":"3698_CR13","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/j.1572-0241.1999.01231.x","volume":"94","author":"T Kawasaki","year":"1999","unstructured":"Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, Sasada Y, Shimizu E, Murohisa G, Koide S, Yoshimi T, Nakamura H, Ohno R (1999) Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 94(7):1918\u20131922. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01231.x","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3698_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s1499-3872(15)60379-4","volume":"14","author":"YM Zhang","year":"2015","unstructured":"Zhang YM, Yu W, Zhou N, Li JZ, Xu LC, Xie ZY, Lu YF, Li LJ (2015) High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int 14(3):287\u2013292. https:\/\/doi.org\/10.1016\/s1499-3872(15)60379-4","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"3698_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10156-010-0188-8","volume":"17","author":"S Ikuta","year":"2011","unstructured":"Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, Beppu N, Kurimoto A, Yanagi H, Mitsunobu M, Yamanaka N (2011) Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J Infect Chemother 17(3):388\u2013391. https:\/\/doi.org\/10.1007\/s10156-010-0188-8","journal-title":"J Infect Chemother"},{"key":"3698_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","volume":"96","author":"L Dou","year":"2020","unstructured":"Dou L, Meng D, Dong Y, Chen L, Han X, Fan D, Dong H (2020) Dosage regimen and toxicity risk assessment of linezolid in sepsis patients. Int J Infect Dis 96:105\u2013111. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.054","journal-title":"Int J Infect Dis"},{"key":"3698_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02387-18","author":"SC Li","year":"2019","unstructured":"Li SC, Ye Q, Xu H, Zhang L, Wang Y (2019) Population pharmacokinetics and dosing optimization of linezolid in pediatric patients. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02387-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3698_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2147\/dddt.S303497","volume":"15","author":"X Wang","year":"2021","unstructured":"Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z, Luo J, Qiu B, Li Z, Wang Y, Wu Z, Lan J, Chen C (2021) Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther 15:2129\u20132141. https:\/\/doi.org\/10.2147\/dddt.S303497","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"3698_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y (2014) Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents 44(3):242\u2013247. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"3698_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40268-015-0117-5","volume":"16","author":"NR Srinivas","year":"2016","unstructured":"Srinivas NR, Syed M (2016) Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: superiority of Ctrough- over Cmax-derived linear regression models. Drugs R D 16(1):69\u201379. https:\/\/doi.org\/10.1007\/s40268-015-0117-5","journal-title":"Drugs R D"},{"key":"3698_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jconrel.2022.11.014","volume":"352","author":"R Ota","year":"2022","unstructured":"Ota R, Yamashita F (2022) Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics. J Control Release 352:961\u2013969. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.014","journal-title":"J Control Release"},{"issue":"2","key":"3698_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/ftd.0000000000001078","volume":"45","author":"EA Poweleit","year":"2023","unstructured":"Poweleit EA, Vinks AA, Mizuno T (2023) Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. Ther Drug Monit 45(2):143\u2013150. https:\/\/doi.org\/10.1097\/ftd.0000000000001078","journal-title":"Ther Drug Monit"},{"issue":"12","key":"3698_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/psp4.12870","volume":"11","author":"J Gill","year":"2022","unstructured":"Gill J, Moullet M, Martinsson A, Miljkovi\u0107 F, Williamson B, Arends RH, Pilla Reddy V (2022) Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug-drug interaction prediction. CPT Pharmacometrics Syst Pharmacol 11(12):1560\u20131568. https:\/\/doi.org\/10.1002\/psp4.12870","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3698_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105578","volume":"167","author":"JB Woillard","year":"2021","unstructured":"Woillard JB, Labriffe M, Pr\u00e9maud A, Marquet P (2021) Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus. Pharmacol Res 167:105578. https:\/\/doi.org\/10.1016\/j.phrs.2021.105578","journal-title":"Pharmacol Res"},{"issue":"4","key":"3698_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11095-022-03252-8","volume":"39","author":"M Bououda","year":"2022","unstructured":"Bououda M, Uster DW, Sidorov E, Labriffe M, Marquet P, Wicha SG, Woillard JB (2022) A machine learning approach to predict interdose vancomycin exposure. Pharm Res 39(4):721\u2013731. https:\/\/doi.org\/10.1007\/s11095-022-03252-8","journal-title":"Pharm Res"},{"issue":"1","key":"3698_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/s-0038-1676805","volume":"39","author":"B Kok","year":"2019","unstructured":"Kok B, Abraldes JG (2019) Child-Pugh classification: time to abandon? Semin Liver Dis 39(1):96\u2013103. https:\/\/doi.org\/10.1055\/s-0038-1676805","journal-title":"Semin Liver Dis"},{"issue":"1","key":"3698_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"4","key":"3698_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijantimicag.2011.05.007","volume":"38","author":"H Dong","year":"2011","unstructured":"Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H (2011) Clinical pharmacokinetic\/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 38(4):296\u2013300. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.05.007","journal-title":"Int J Antimicrob Agents"},{"key":"3698_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00133-20","author":"SH Zhang","year":"2020","unstructured":"Zhang SH, Zhu ZY, Chen Z, Li Y, Zou Y, Yan M, Xu Y, Wang F, Liu MZ, Zhang M, Zhang BK (2020) Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00133-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3698_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13613-023-01184-z","volume":"13","author":"T Tikiso","year":"2023","unstructured":"Tikiso T, Fuhrmann V, K\u00f6nig C, Jarczak D, Iwersen-Bergmann S, Kluge S, Wicha SG, Grensemann J (2023) Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study. Ann Intensive Care 13(1):83. https:\/\/doi.org\/10.1186\/s13613-023-01184-z","journal-title":"Ann Intensive Care"},{"key":"3698_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Hu Y, Xu P, Xu T, Chen C, He L, Zhou M, Chen Z, Zhang C, Yu X, Fang L, Zhu J, Ji Y, Lin Q, Cao H, Dai Y, Lu X, Shi C, Li L, Wang C, Li X, Fang Q, Miao J, Zhu Z, Lin G, Zhan H, Lv S, Zhu Y, Cai X, Ying Y, Chen M, Xu Q, Zhang Y, Xu Y, Federico P, Jiang S, Dai H (2022) Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health 10:967311. https:\/\/doi.org\/10.3389\/fpubh.2022.967311","journal-title":"Front Public Health"},{"issue":"3","key":"3698_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/03602532.2016.1188938","volume":"48","author":"M Murray","year":"2016","unstructured":"Murray M (2016) CYP2J2 - regulation, function and polymorphism. Drug Metab Rev 48(3):351\u2013368. https:\/\/doi.org\/10.1080\/03602532.2016.1188938","journal-title":"Drug Metab Rev"},{"issue":"9","key":"3698_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","volume":"17","author":"I Bi\u00e8che","year":"2007","unstructured":"Bi\u00e8che I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I (2007) Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17(9):731\u2013742. https:\/\/doi.org\/10.1097\/FPC.0b013e32810f2e58","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"3698_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/21.1.1","volume":"21","author":"PG Davey","year":"1988","unstructured":"Davey PG (1988) Pharmacokinetics in liver disease. J Antimicrob Chemother 21(1):1\u20135. https:\/\/doi.org\/10.1093\/jac\/21.1.1","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"3698_CR35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147\u20131161. https:\/\/doi.org\/10.1007\/s00228-008-0553-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"3698_CR36","doi-asserted-by":"publisher","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","volume":"51","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP (2003) Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51(Suppl 2):ii17-25. https:\/\/doi.org\/10.1093\/jac\/dkg248","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3698_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.drudis.2021.09.013","volume":"27","author":"KV Danishuddin","year":"2022","unstructured":"Danishuddin KV, Faheem M, Woo Lee K (2022) A decade of machine learning-based predictive models for human pharmacokinetics: advances and challenges. Drug Discov Today 27(2):529\u2013537. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.013","journal-title":"Drug Discov Today"},{"issue":"6","key":"3698_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","volume":"33","author":"HY Dong","year":"2014","unstructured":"Dong HY, Xie J, Chen LH, Wang TT, Zhao YR, Dong YL (2014) Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis 33(6):1029\u20131035. https:\/\/doi.org\/10.1007\/s10096-013-2041-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"3698_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1445-5994.2009.01996.x","volume":"39","author":"CY Cheah","year":"2009","unstructured":"Cheah CY, De Keulenaer B, Leahy MF (2009) Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern Med J 39(9):619\u2013623. https:\/\/doi.org\/10.1111\/j.1445-5994.2009.01996.x","journal-title":"Intern Med J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03698-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03698-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03698-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:05:56Z","timestamp":1720163156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03698-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3698"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03698-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (Xi\u2019an, China). The institutional review board (IRB) approval number was \u201c[XJTU1AF2019LSK-163].\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}